Publicacións en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (111)

2024

  1. Applicability of the Barcelona scale to assess the quality of cleanliness of mucosa at esophagogastroduodenoscopy

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 3, pp. 246-252

  2. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

    Therapeutic Advances in Gastroenterology, Vol. 17

  3. Combination of granulocyte–monocyte apheresis and tofacitinib: Multicentre and retrospective study

    Gastroenterologia y Hepatologia

  4. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 18, Núm. 1, pp. 65-74

  5. Contraceptive Recommendations for Women with Immune-Mediated Inflammatory Diseases: A Delphi Consensus

    Advances in Therapy, Vol. 41, Núm. 4, pp. 1372-1384

  6. Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 18, Núm. 4, pp. 578-588

  7. Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 12, pp. 1604-1615

  8. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU

    Revista espanola de enfermedades digestivas, Vol. 116, Núm. 2, pp. 83-113

  9. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432

  10. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on sexuality and inflammatory bowel disease

    Gastroenterologia y Hepatologia

  11. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

    Alimentary Pharmacology and Therapeutics

  12. Recommendations on the management of severe obesity in patients with inflammatory bowel disease of the Spanish Group on Crohn's Disease and Ulcerative Colitis (GETECCU), Spanish Society of Obesity (SEEDO), Spanish Association of Surgery (AEC) and Spanish Society of Digestive Endoscopy (SEED)

    Gastroenterologia y Hepatologia

  13. Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study

    Journal of Clinical Medicine, Vol. 13, Núm. 2

  14. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology

  15. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 5, pp. 522-552